Avraham Pharmaceuticals

Avraham Pharmaceuticals ("Avraham") is a privately held emerging pharmaceutical company developing new products for the treatment and/or prevention of neurodegenerative diseases. Founded in 2010, Avraham has raised $9 million to conduct a European Phase II proof-of-concept efficacy trial for Alzheimer's disease patients, supporting the development of its lead product candidate, ladostigil.